Alex Herrera is a Hematologist and a Hematologist Oncology expert in Duarte, CA. Herrera has been practicing medicine for over 14 years and is rated as an Elite expert by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). He is also highly rated in 22 other conditions, according to our data. His top areas of expertise are Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Herrera is currently accepting new patients.
Matthew Matasar is a Hematologist Oncology expert in New York, New York. Matasar has been practicing medicine for over 23 years and is rated as an Elite expert by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). He is also highly rated in 29 other conditions, according to our data. His top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, and Bone Marrow Transplant. Matasar is currently accepting new patients.
Jane Winter is a Hematologist and a Hematologist Oncology expert in Chicago, Illinois. Winter has been practicing medicine for over 46 years and is rated as an Elite expert by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). She is also highly rated in 20 other conditions, according to our data. Her top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Winter is currently accepting new patients.
Summary: This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed D...
Summary: This Phase Ib, open-label, multicenter study evaluates the safety, efficacy, and pharmacokinetics of venetoclax in combination with Pola + R-CHP in previously untreated participants with BCL-2 IHC-positive DLBCL. Approximately 50 participants will be enrolled in this study in five consecutive cohorts each consisting of approximately 10 participants.